Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 12/02/25 | 8-K | Current report |
|
  |
5 |
| 11/19/25 | 425 | Prospectuses and communications, business combinations |
|
2 | |
| 11/19/25 | 425 | Prospectuses and communications, business combinations |
|
1 | |
| 11/18/25 | 425 | Prospectuses and communications, business combinations |
|
1 | |
| 11/18/25 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
|
3 | |
| 11/18/25 | 425 | Prospectuses and communications, business combinations |
|
5 | |
| 11/18/25 | 8-K | Current report |
|
|
5 |
| 11/12/25 | 425 | Prospectuses and communications, business combinations |
|
28 | |
| 10/27/25 | 424B3 | Prospectus [Rule 424(b)(3)] |
|
507 | |
| 10/27/25 | DEFM14A | Definitive proxy statement relating to merger or acquisition |
|
510 |
